文献速递神经免疫

那他珠单抗、芬戈莫德与富马酸二甲酯使用及多发性硬化女性妊娠相关复发与残疾

Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
PubMed 文献 · Neurology · 2021-06-15

孕前年化复发率(ARR)为0.29,孕晚期降至0.19,产后早期升至0.59。那他珠单抗持续至妊娠可降低孕期复发风险,产后重启那他珠单抗可预防产后复发,母乳喂养与较低复发风险相关。

要点

  • 孕前ARR为0.29,孕晚期降至0.19,产后早期升至0.59。
  • 那他珠单抗持续至妊娠降低孕期复发风险(OR 0.76/月)。
  • 产后重启那他珠单抗预防复发(HR 0.11),母乳喂养降低复发风险(HR 0.61)。

核心结论

  • 停用那他珠单抗或芬戈莫德后,多发性硬化女性孕期和产后复发概率增加。

主要发现

  • 孕前ARR为0.29(95% CI 0.27-0.32),孕晚期降至0.19(0.14-0.24),产后早期升至0.59(0.51-0.67)。
  • 使用芬戈莫德或那他珠单抗者孕前ARR分别为0.37(0.28-0.49)和0.29(0.22-0.37),孕期ARR升高。
  • 孕前使用富马酸二甲酯者孕期ARR降低;所有DMT组产后ARR均骤升。
  • 那他珠单抗持续至妊娠降低孕期复发风险(OR 0.76/月[0.60-0.95],p=0.017)。
  • 产后重启那他珠单抗预防复发(HR 0.11[0.04-0.32],p<0.0001);母乳喂养者复发风险较低(HR 0.61[0.41-0.91],p=0.016)。

临床怎么用

  • 对高复发风险女性,孕前使用那他珠单抗并持续至妊娠34周、产后早期重启,可有效降低复发风险。
  • DMT使用策略需权衡潜在的胎儿/新生儿并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort. METHODS: Using data from the MSBase Registry, we included pregnancies conceived after 31 Dec 2010 from women with relapsing-remitting MS or clinically isolated syndrome. Predictors of intrapartum relapse, and postpartum relapse and disability progression were determined by clustered logistic regression or Cox regression analyses. RESULTS: We included 1998 pregnancies from 1619 women with MS. Preconception annualized relapse rate (ARR) was 0.29 (95% CI 0.27-0.32), fell to 0.19 (0.14-0.24) in third trimester, and increased to 0.59 (0.51-0.67) in early postpartum. Among women who used fingolimod or natalizumab, ARR before pregnancy was 0.37 (0.28-0.49) and 0.29 (0.22-0.37), respectively, and increased during pregnancy. Intrapartum ARR decreased with preconception dimethyl fumarate use. ARR spiked after delivery across all DMT groups. Natalizumab continuation into pregnancy reduced the odds of relapse during pregnancy (OR 0.76 per month [0.60-0.95], p=0.017). DMT re-initiation with natalizumab protected against postpartum relapse (HR 0.11 [0.04-0.32], p<0.0001). Breastfeeding women were less likely to relapse (HR 0.61 [0.41-0.91], p=0.016). 5.6% of pregnancies were followed by confirmed disability progression, predicted by higher relapse activity in pregnancy and postpartum. CONCLUSION: Intrapartum and postpartum relapse probabilities increased among women with MS after natalizumab or fingolimod cessation. In women considered to be at high relapse risk, use of natalizumab before pregnancy and continued up to 34 weeks gestation, with early re-initiation after delivery is an effective option to minimize relapse risks. Strategies of DMT use have to be balanced against potential fetal/neonatal complications.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Yeh WZ, Widyastuti PA, Van der Walt A, et al. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology. 2021. PMID: 33879599. doi:10.1212/WNL.0000000000012084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。